How impactful is your exhibitor booth going to be at AACC?

Navigating the complex dynamics of conference exhibitions is…

In-vitro diagnostics | Uncategorised | Global | IVD Gateway | LabPRO Plus | Size and Share Plus

Most common cancer biomarkers for Europe NGS testing: RAS, BRAF, EGFR

Most-commonly tested cancer biomarkers using NGS in Europe…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)

Larger gene panels are the predominant NGS testing strategy in EU5

Larger gene panels are the predominant NGS testing strategy…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)

Europe: precision medicine and access to NGS cancer biomarker testing

Precision medicine and access to NGS cancer biomarker…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)

Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019

Proportion of cancer biomarker testing done with NGS…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)